We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

157 hedge funds and large institutions have $542M invested in Immunogen Inc in 2017 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 9

155% more call options, than puts

Call options by funds: $4.33M | Put options by funds: $1.7M

107% more capital invested

Capital invested by funds: $262M → $542M (+$280M)

16% more funds holding

Funds holding: 135157 (+22)

9% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 46

Holders
157
Holders Change
+22
Holders Change %
+16.3%
% of All Funds
3.91%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
32
Increased
42
Reduced
46
Closed
9
Calls
$4.33M
Puts
$1.7M
Net Calls
+$2.63M
Net Calls Change
+$2.96M

IMGN Hedge Fund Activity: Q2 2017 in Review

157 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2017, worth a combined $542M — up 107% from $262M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new IMGN positions and 9 closed out — a net gain of 23 holders — while 42 added to existing stakes and 46 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22M. The largest seller was OrbiMed, cutting an estimated $9.87M.

  • 157 institutional investors held Immunogen Inc (IMGN) as of Q2 2017, up from 135 in Q1 2017.
  • Funds reported $542M of Immunogen Inc stock for Q2 2017, up 107% quarter-over-quarter.
  • 32 funds opened new Immunogen Inc positions in Q2 2017 and 9 closed out, a net change of +23 holders.
  • The largest Immunogen Inc buyer in Q2 2017 was Fidelity Investments, an estimated $22M added.
  • The largest Immunogen Inc seller in Q2 2017 was OrbiMed, an estimated $9.87M sold.

Based on aggregated 13F filings for Q2 2017.